Leukotriene Receptor Antagonist

Leukotriene Receptor Antagonists (42):

Cat. No.	Product Name	Effect	Purity

HY-108396

γ-Linolenic acid ethyl ester	Antagonist	99.14%
γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B₄ receptor 4 (LTB₄) antagonist.

HY-117896

SC-50605	Antagonist
SC-50605 and SC-51146 are second-generation leukotriene B4 (LTB4) receptor antagonists that effectively inhibit LTB4-induced chemotaxis in guinea pigs. SC-50605 targets the LTB4 receptor and has the potential to inhibit inflammatory diseases such as asthma, rheumatoid arthritis, and skin diseases..

HY-114641

BIIL-260	Antagonist
BIIL-260 is a potent and long-acting orally active leukotriene B(4) receptor LTB₄ antagonist, with anti-inflammatory activity. BIIL-260 interacts with the LTB₄ receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB₄ receptor on isolated human neutrophil cell membranes with the K_i value of 1.7 nM.

HY-101676

RG-12525	Antagonist	98.31%
RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC₅₀s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC₅₀ of appr 60 nM and a potent inhibitor of CYP3A4, with a K_i value of 0.5 µM.

HY-111212

Tomelukast	Antagonist	≥99.0%
Tomelukast (LY171883) is an orally active leukotriene D₄ and E₄ antagonist. Tomelukast can be used for the research of asthma.

HY-13315S1

Montelukast-d₆ sodium	Antagonist
Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

HY-107610

SR2640 hydrochloride	Antagonist	99.60%
SR2640 (hydrochloride) is a potent and selective competitive leukotriene D4/leukotriene E4 antagonist. SR2640 can be used for researching the role of leukotrienes in human asthma.

HY-145234

GPBAR1-IN-3	Antagonist
GPBAR1-IN-3 (Compound 14) is a selective GPBAR1 agonist (EC₅₀=0.17 μM) and a CysLT₁R antagonist.

HY-105221

Masilukast	Antagonist
Masilukast is an orally administered cysteinyl leukotriene D₄ (LTD₄) receptor antagonist with potential to research asthma.

HY-17492S2

Zafirlukast-¹³C,d₆	Antagonist
Zafirlukast-¹³C,d₆ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-13315S

Montelukast-d₆	Antagonist
Montelukast-d₆ is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

HY-113758

LY 163443	Antagonist
LY 163443 is a selective antagonist of leukotrienes D4 (LTD4) and E4 (LTE4). LY 163443 can antagonize LTD4-induced contractions of guinea pig ileum, trachea, and lung parenchyma. LY 163443 also inhibits tracheal contractions to LTE4.

HY-19042

YM-16638	Antagonist
YM-16638 is an orally active leukotriene (LT) antagonist. YM-16638 can inhibit the production of LTC₄, LTD₄, and LTE₄ in guinea pig trachea, with IC₅₀ values of 0.05 μM, 0.16 μM, and 0.096 μM, respectively. YM-16638 has a dose-dependent inhibitory effect on antigen-induced early and late respiratory responses in allergic sheep.

HY-107611

Ro 24-5913	Antagonist
Ro 24-5913 (Cinalukast) is an orally active and potent LTD4 antagonist with an IC₅₀ value of 6.4 nM. Ro 24-5913 can be used for the research of asthma.

HY-17492S1

Zafirlukast-¹³C,d₃	Antagonist
Zafirlukast-¹³C,d₃ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-117943

(rac)-ONO-2050297	Antagonist
(rac)-ONO-2050297 is a benzoxazole derivative and a potent biCysLT1/CysLT2 antagonist with IC₅₀ values ??are 17 nM and 0.87 nM respectively.

HY-13315R

Montelukast sodium (Standard)	Antagonist
Montelukast (sodium) (Standard) is the analytical standard of Montelukast (sodium). This product is intended for research and analytical applications. Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research.

HY-112532

REV 5901	Antagonist	≥99.0%
REV 5901 is a competitive and orally active antagonist of leukotriene receptor, with a K_i of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved.

HY-149084

LTB4 antagonist 3	Antagonist
LTB4 antagonist 3 (compound 24e) is a leukotriene B4 (LTB4) antagonist with an IC₅₀ value of 477 nM. LTB4 antagonist 3 has anti-inflammatory activity.

HY-112736

RG 14893	Antagonist
RG 14893 is a high affinity, competitive, orally active leukotriene B4 receptor antagonist.

Name
Email *

	Sorry, but the email address you supplied was invalid.